2015 American Transplant Congress
Outcomes Following Kidney Transplant With Low Level Positive Flow Cytometric Crossmatch
Introduction: Highly-sensitized kidney transplant (KTx) candidates have difficulty finding a negative crossmatch donor. KTx with low level positive crossmatch might be the next best option.…2015 American Transplant Congress
Angiotensin Receptor Antibody IgG1 Subclass Predicts Accelerated Graft Loss in Those Kidney Transplant Recipients Who Develop Biopsy Proven Transplant Glomerulopathy Irrespective of the Presence Or Absence of Donor Specific Anti HLA Antibodies
We assessed the presence or absence of angiotensin receptor antibodies (ATRab) in all those Kidney Transplant Patients who have had biopsy proven transplant glomerulopathy (TG)…2015 American Transplant Congress
Basiliximab Induction With Delayed Tacrolimus Initiation up to 14 Days Post Liver Transplantation Maintains Excellent Clinical Outcomes While Preserving Renal Function
University of Virginia Health System, Charlottesville, VA.
Background: Calcineurin inhibitors are frequently delayed to allow for recovery of renal function after transplantation; however, there is a paucity of literature supporting a delay…2015 American Transplant Congress
Clinical Outcome of Patients With De Novo C1q Binding Donor-Specific HLA Antibodies After Renal Transplantation
A. Not all de novo donor-specific HLA antibodies (dnDSA) are causing immediate graft loss. The importance of complement-binding DSA was recently shown with a commercial…2015 American Transplant Congress
Structural and Functional Basis for Non-HLA Antibody Mediated AT1R Activation
Nephrology and Intensive Care Medicine, Charité University Hospital, Berlin, Germany.
Angiotensin II type receptor (AT1R), a heptahelical protein signals stimuli upon binding of natural peptide ligand angiotensin II (Ang II) and the pathogenic non-HLA IgG…2015 American Transplant Congress
Infectious Complications With Plasmapheresis in Combination With Antithymocyte Globulin Compared to Antithymocyte Globulin Alone in the Treatment of Acute Rejection
The Comprehensive Transplant Center, The Ohio State University Wexner Medical Center, Columbus, OH.
Background: Due to the complex nature of acute rejection (AR), multiple therapeutic modalities are necessary to prevent graft loss. The combination of prolonged cell depletion…2015 American Transplant Congress
The Potential Use of the Plasma Biomarker CXCL9 (MIG), Interleukin 2 Receptor alpha (IL2Rα) and SCGF-b as Predictors of Renal Graft Rejection
Background: Early detection of rejection in kidney transplantation is crucial, and predictive plasma biomarkers are highly desirable as non-invasive tests.Methods: From a cohort of 120…2015 American Transplant Congress
Intra-Lymphocyte Concentrations of Mycophenolic Acid Correlate With the Incidence of Early Graft Rejection in Renal Transplant Recipients
Introduction: Although routine therapeutic drug monitoring of mycophenolic acid (MPA) concentrations in plasma has been recommended to individualize MPA doses in transplant recipients, little is…2015 American Transplant Congress
Is There a Protective Value for Low Level Donor Specific Antibodies to Prevent Cardiac Allograft Vasculopathy After Heart Transplant?
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Donor specific antibodies (DSA) following heart transplant has been reported to be associated with increased development of cardiac allograft vasculopathy (CAV) and risk of…2015 American Transplant Congress
Impact of Donor Specific Antibodies in the Older Kidney Transplant Recipient
Houston Methodist Hospital, Houston.
Recent evidence suggests that renal transplant recipients (RTR) with both rejection and donor specific antibodies (DSA) are at high risk of graft loss. Concurrently, the…
- « Previous Page
- 1
- …
- 163
- 164
- 165
- 166
- 167
- …
- 172
- Next Page »